At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 17 enrolled
Drug / intervention
Cabozantinibdrug
Likely dose
Cabozantinib 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases
In Brief
A Phase 2 clinical trial evaluating Cabozantinib for Prostate Cancer. Completed, enrolled 17 participants across 1 site.
Detailed Summary
This research study is being done to measure the clinical benefit associated with cabozantinib (XL184) in men who have prostate cancer that has spread to visceral organs (organs other than bone or lymph nodes) and no longer responds to initial hormonal (castration) therapy. This type of prostate cancer is called metastatic, castrate-resistant prostate cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 2013
Enrollment StartApr 2013
Primary CompletionJul 2016
TodayJul 2026
First PostedApr 18, 2013
Enrollment StartApr 30, 2013
Primary CompletionJul 18, 2016
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 13.2 years ago
Interventions
Cabozantinibdrug
Cabozantinib 60 mg daily (oral). Subjects may continue to receive study treatment until they experience unacceptable drug-related toxicity or disease progression.